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Abstract
Many patients with stage I non-small cell lung carcinoma will develop recurrence following
surgical excision. Sox2 is a marker of embryonic stem cell pluripotency that is associated with
aggressive tumor behavior and is expressed in a subset of lung adenocarcinomas. We hypothesized
that Sox2 expression may provide prognostic information in early stage lung adenocarcinomas.
We evaluated formalin-fixed paraffin embedded tissue from 104 stage I lung adenocarcinomas
resected between 1997 and 2000. Sox2 expression was analyzed by immunohistochemistry and
compared to clinicopathologic features, time-to-progression (TTP) and overall survival (OS).
Sox2 expression was detected in 50% of cases and was more frequent in tumors from older and
male patients but not significantly associated with smoking status, tumor stage, grade, or
histologic subtype. Compared to Sox2-negative tumors, Sox2 expression predicted a shorter TTP
(49% versus 82% at 5 years; P = 0.0006) and shorter OS (54% versus 79% at 5 years; P = 0.004).
By multivariate analysis, Sox2 expression predicted a greater risk of progression among men
(hazard ratio [HR] 5.6; 95% CI 2.3 to 13.8) and women (HR 2.1; 95% CI 0.8 to 5.7). Sox2
expression was associated with significantly shorter OS among men (HR 2.5; 95% CI 1.2 to 5.1),
but not in women. Sox2 appears to be an independent predictor of poor outcome in stage I lung
adenocarcinomas and may help stratify patients at increased risk for recurrence.
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INTRODUCTION
Lung cancer is among the most common and morbid cancers in the United States.(15,16)
The majority of lung cancers are non-small cell carcinomas (NSCLC), the most common
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types of which are adenocarcinoma (ACA) and squamous cell carcinoma (SCC). While SCC
has been decreasing in incidence with changes in smoking patterns, ACA is increasing in
incidence, particularly among women.(25) NSCLC mortality is predicted in large part by
tumor stage, with a median survival of more than 8 years for stage I and less than 1 year for
stage IV patients.(9) Although surgery can be curative for early stage disease,(6) a
significant subset of these patients develop metastases.
Several groups have attempted to identify markers of more aggressive tumor behavior using
gene expression profiling;(7,11,20–22) however, this approach is hampered by the lack of
overlap between gene signatures identified by individual groups, a problem thought to be
related to tumor heterogeneity and varying statistical approaches.(5) Immunohistochemistry
is a potentially more cost-effective and faster way to identify tumor signatures via their
protein expression profiles.(29,30) However, to date there is no single IHC marker that is
used routinely for prognostic purposes in early stage NSCLC.
Sox2 is a transcription factor that is involved in the maintenance of embryonic stem cell
pluripotency(14,27) and in multiple developmental processes, including lung branching
morphogenesis.(13) In tumor gene expression studies, analyses of genes known to be active
in development and differentiation have shown that Sox2 is overexpressed in certain poorly
differentiated subtypes of cancer.(3,8) A cancer therapy outcome predictor algorithm that
incorporates genomic analysis of "stemness" pathways, including the Nanog/Oct4/Sox2
(NOS) pathway, demonstrates high prognostic accuracy in retrospective studies of patients
with multiple tumor types, including lung cancer.(10)
Expression of Sox2 protein has not been extensively studied in lung cancer; however, we
have recently demonstrated that Sox2 is strongly and diffusely expressed in ~90% of
pulmonary SCC and ~20% of ACA.(23) Given the association between NOS pathway gene
expression and aggressive tumor types, and given the fact that Sox2 is expressed in a subset
of ACA, we hypothesized that Sox2 may be associated with poor prognosis in lung ACA.
The purpose of this retrospective study was to evaluate the prognostic value of Sox2
expression in surgically resected stage I lung ACA.
MATERIALS AND METHODS
Study Population
We collected 151 consecutive cases of surgically resected Stage I lung ACA (T1 N0 M0 or
T2 N0 M0) in the period ranging from 1997–2000 from the pathology files of Brigham and
Women's Hospital (BWH), following approval by the Partners Institutional Review Board
(Partners IRB # 2009P001426 and 2006P001921). Diagnoses were confirmed, tumors were
graded and subtyped according to WHO criteria,(26) and staged according to the American
Joint Committee on Cancer criteria by three pathologists (LMS, JAB, LRC).(9) On review,
five tumors were re-classified as adenosquamous or large cell neuroendocrine carcinomas
and were excluded from further analysis.
Patient demographic and outcome data were retrieved from the electronic medical records;
24 patients were lost to follow-up and were excluded. Four patients with concurrent cancer
diagnoses (not including skin squamous cell and basal cell carcinomas) were excluded. Of
the remaining patients, 14 had insufficient tissue for immunohistochemical studies, leaving
104 cases for the final analysis.
Immunohistochemistry
Sox2 expression was evaluated on 37 ACA included in a tissue microarray (TMA) that was
previously described(1) and 67 ACA using whole tissue sections. Briefly, a TMA of
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formalin-fixed, paraffin-embedded tumor containing three 0.6 mm cores from each sample
was constructed. The areas included on the TMA were carefully selected to ensure that
heterogeneous tumors were well-represented. Immunohistochemistry for Sox2 (rabbit
polyclonal antibody; 1:500 dilution; Novus Biologicals, Littleton, CO, USA), TTF-1 (Clone
8G7G3/1; 1:1000 dilution; Dako, Carpinteria, CA), Nanog (goat polyclonal; 1:500 dilution;
R&D Systems, Minneapolis, MN) and Oct3/4 (rabbit polyclonal; 1:150 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA) were performed following heat-induced epitope retrieval in
citrate buffer (pH 6) using a pressure cooker.
Nuclear staining was considered positive. We graded the immunoreactivity by two
methodologies: (1) semiquantitatively with 0 as no staining; 1+, <5% tumor cells staining;
2+, 5–25% tumor cells staining; 3+, 26–50% tumor cells staining; and 4+, >50% tumor cells
staining; and (2) as negative or positive utilizing a 5% cut-off.
Statistical Analysis
Comparison of clinicopathologic characteristics and Sox2 expression was performed using
the Wilcoxon rank-sum and Fisher’s exact tests. The median potential follow-up time using
censored data was 96 months. Time-to-progression was computed from time of surgery to
time of clinical diagnosis of recurrent carcinoma; patients who died without documentation
of recurrence were censored. Overall survival was calculated from time of surgery to time of
death from any cause or to time of last follow-up, at which point the data were censored.
The logrank (Mantel-Cox) test and Kaplan-Meier estimation were used to examine the time
to progression and overall survival. The Cox proportional hazards model was used to
perform regression analysis of the failure time data. In addition to controlling for stage,
which is prognostic for NSCLC, the multivariate analysis was adjusted for the
clinicopathologic characteristics that were associated with Sox2 expression. All reported P-
values are based on a two-sided hypothesis. The data analysis was conducted primarily
using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA) and SAS 9.1 (SAS
Institute Inc., Cary, NC).
RESULTS
Patient Demographics and Pathologic Characteristics
Patient demographic and surgical and tumor pathologic data are detailed in Table 1. There
were relatively more women in the study. The majority of patients were smokers. 50% of
patients were stage IA and 50% of patients were stage IB. 82% of cases had mixed-subtype
histology. Acinar pattern was most commonly the predominant subtype (51%), followed by
papillary (18%), solid (17%), and bronchioloalveolar (13%). Of the 19 cases that contained
a single histologic subtype, 7 (37%) were acinar, 5 (26%) were papillary, and 7 (37%) were
solid. None of the cases were pure bronchioloalveolar carcinomas.
Sox2 Expression in Lung Adenocarcinoma
Using the semiquantitative scoring system, 36 (35%) cases had no Sox2 staining (0), 16
(15%) cases had <5% tumor cells staining (1+), 14 (13%) cases had 5–25% tumor cells
staining (2+), 20 (19%) cases had 26–50% tumor cells staining (3+), and 18 (17%) had
>50% tumor cells staining (4+). This is consistent with previously reported data.(23) Using
the 5% cut-off, Sox2 expression was observed in 17 of 37 (46%) cases evaluated by TMA
and in 35 of 67 (52%) cases evaluated as whole tissue sections (P=0.68). Overall, 52 (50%)
cases were considered positive using this cut-off (see below). Representative images of Sox2
expression in low and high grade tumors are shown in Figure 1.
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TTF-1 was positive in 92 (88%) cases. Oct3/4 and Nanog protein expression was very weak
and was detected in only rare cells in 8% and 7% of cases, respectively. Based on a 5% cut-
off, both markers were considered negative in all cases.
Patient clinical characteristics were correlated with Sox2 expression (Table 2). Median age
was higher in patients with Sox2-positive tumors (69 vs. 64 years, P = 0.05). Patients older
than 60 years were more likely than those less than 60 years to have Sox2-positive tumors
(58% vs. 35%, P = 0.04). Sox2-positive tumors were more frequent in men (61%) than in
women (44%); however, this difference was not statistically significant (P=0.15). There was
no significant difference in Sox2 expression based on smoking status or resection type.
Tumor pathologic characteristics were correlated with Sox2 expression (Table 3). There was
no difference in the average size of Sox2-negative and Sox2-positive tumors (2.4 cm vs. 2.5
cm). Tumors with pleural invasion were more likely to show Sox2 expression than those
without pleural invasion (61% vs. 44%); however, this difference was not statistically
significant (P = 0.14). There was no significant difference in Sox2 expression based on
tumor stage, grade, or dominant histologic subtype. Of note, both adenocarcinomas in our
study that had prominent mucinous features were strongly Sox2-positive.
One Sox2-negative and two Sox2-positive tumors had positive surgical margins, none of
whom received adjuvant therapy. Margins could not be assessed in two cases. Three patients
with Sox2-negative tumors and three patients with Sox2-positive tumors received adjuvant
therapy (four patients received local radiotherapy only; one patient with a Sox2-negative
tumor received both radiotherapy and chemotherapy and one patient with a Sox2-positive
tumor received chemotherapy only).
Survival Analysis
Univariate survival analysis was performed for each cut-off in the semiquantitative Sox2
scoring system; >5% tumor cell staining proved to be the strongest predictor of survival
(data not shown), and this cut-off was therefore used for the analyses.
By univariate analysis, Sox2 expression predicted a shorter time to progression (P =
0.0006). At five years, 82% of the patients with Sox2-negative ACA and 49% of patients
with Sox2-positive ACA were disease-free. Exploring the interaction between Sox2
expression and patient sex, men and women with Sox2-negative tumors had virtually
identical TTP curves (P = 0.59). Although Sox2-positive ACA are associated with shorter
time-to-progression among both genders (Figure 2), men with Sox2-positive tumors had
significantly shorter TTP than did women (P = 0.03). Accounting for the sex differences as
well as controlling for age and stage, the risk of progression was more than five times higher
(HR 5.6; 95% CI 2.3–13.8) among male patients with Sox2-positive tumors (P = 0.0002). In
contrast, women with Sox2-positive tumors were twice as likely to progress (HR 2.1; 95%
CI 0.8–5.7) compared to all those with Sox2-negative tumors (P = 0.12), but this difference
was not statistically significant.
By univariate analysis, Sox2 expression was also a significant predictor of a shorter overall
survival (P = 0.004). The overall survival at five years was 79% in the Sox2-negative group
and 54% in the Sox2-positive tumors (Figure 3). After allowing for differential sex effects as
well as adjusting for age and stage, Sox2 expression is associated with more than double the
risk of dying (HR 2.5; 95% CI 1.2–5.1) among male patients compared to all those with
Sox2-negative tumors (P = 0.01). In contrast, the risk of death is increased moderately (HR
1.6; 95% CI 0.8–3.2) for female patients, but this difference was not statistically significant
(P = 0.2).
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Of the 52 patients with Sox2-positive tumors, 23 (44%) had clinically documented
progression: 11 patients developed metastatic disease and 12 patients had a local recurrence.
During the same period, of the 52 patients with Sox2-negative tumors, eight (15%) had
progression: five patients developed metastatic disease and three had a local recurrence.
Discussion
There is a pressing need for additional markers to provide prognostic information in early
stage lung cancer, as the current surgical-pathologic staging system cannot predict which
stage I lung cancers will be cured by surgery alone and which will recur. Patients with more
aggressive tumors may benefit from adjuvant therapy, if they can be identified at the time of
surgical resection. A significant effort has been made to identify markers that can provide
this prognostic information in the form of gene expression and immunohistochemical
analysis. Most of the currently available models for prognostication in early stage lung
cancer are not in widespread use, and, in the case of gene expression analysis, are
prohibitively expensive. In Sox2, we have identified a single immunohistochemical marker
that is easily interpreted, inexpensive, and highly associated with shorter time to progression
and overall survival in stage I lung adenocarcinomas.
We examined expression of the transcription factors Nanog, Oct3/4 and Sox2 in surgically
resected lung adenocarcinomas. Prior studies have demonstrated increased gene expression
of Nanog, Oct3/4 and Sox2 and their downstream targets in aggressive tumor types.(3,10)
Of note, in our study only Sox2 showed significant protein expression in tumor cells. This
discrepancy may be a function of the different methodologies employed, but also raises the
possibility that Sox2 is acting independently of its usual cofactors in lung cancer, or
alternatively that the sensitivity of the available antibodies when used for
immunohistochemistry may be too low to detect the levels of Nanog and Oct3/4 expressed
in this tumor type.
We correlated Sox2 expression with patient characteristics, tumor pathology and survival.
Other than a higher frequency observed with older patient age and male sex, Sox2
expression was not significantly associated with any other clinical or pathologic variables,
including histologic subtype, grade, T classification, or TTF-1 expression. Although not
statistically significant, it is interesting to note that Sox2 expression was more commonly
associated with pleural invasion. Preliminary studies of Sox2 in melanoma have suggested
that Sox2 expression may be associated with local tumor progression.(19)
Sox2 was strongly prognostic, even after adjusting for other clinical variables including age
and gender. Sox2 expression was significantly associated with shorter TTP and OS by
univariate and multivariate analyses. Of note, men with Sox2-expressing tumors were more
likely to progress than were women; their risk of death was about double compared to all
those with Sox2-negative tumors.
Possible pitfalls include use of this marker in large cell neuroendocrine carcinomas or
squamous cell carcinomas that may have been misdiagnosed as adenocarcinomas; because
~80% of LCNEC and >90% of pulmonary squamous cell carcinomas show Sox2 expression,
(23) it is unlikely that this marker would have prognostic value in these cases. The utility of
this marker in tumors of mixed adenosquamous histology has not been examined.
The biologic significance of Sox2 overexpression in lung ACA is not yet known. The lack
of correlation between Sox2 and TTF-1 expression in these tumors suggests that its
expression is not related to tumor differentiation pathways. Of note, SOX2 has been
identified as an oncogene that undergoes amplification in lung and esophageal squamous
cell carcinomas.(2) Large scale copy number gains have been reproducibly detected in
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several regions of the NSCLC genome, including at 3q, 5p and 8q.(12,28) Sox2 is located at
3q26. Comparative genomic hybridization studies have demonstrated that >90% of
squamous cell carcinomas and ~20% of adenocarcinomas have copy number gain involving
3q26,(4) essentially the same proportions that have been demonstrated to have high level
Sox2 expression at the protein level.(23) Of note, these studies have found high level
amplification only in SCC.(4) Epigenetic regulation of Sox2 has been shown to drive its
expression in neural systems, with effects on cell proliferation and differentiation.(24) These
observations warrant additional studies to determine the molecular mechanisms of Sox2
expression in ACA. Correlation between Sox2 expression and the mutation status of
established predictive markers such as EGFR and KRAS will be of particular interest.
To date there is no single IHC marker that is used routinely for prognostic purposes in early
stage NSCLC. A recent report has identified a combination of clinical parameters and
immunohistochemical (IHC) marker panels that provide independent prognostic information
in stage IB NSCLC;(30) however, the proposed algorithms are relatively complex and time-
consuming. Sox2 is currently used in clinical practice to aid in identification and subtyping
of germ cell tumors,(28–30) but it has limited known application outside of that context. It
now appears that it can effectively identify those early stage lung adenocarcinomas that are
more likely to recur in the first five years following surgery. The findings in this
retrospective study require prospective validation. In this study, the strength of the
association between Sox2 expression and poor outcomes is on par with that of other
established poor prognostic markers, including lymphovascular invasion, solid histology,
and tumor size.(17,18) However, Sox2 expression appears to be independent of these and
other pathologic features, suggesting that it may serve as a novel prognostic marker,
enabling the identification of those high-risk patients who may benefit from adjuvant
therapy.
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Figure 1.
Lung adenocarcinomas (ACA) show variable Sox2 expression. (A) Well-differentiated ACA
with papillary features and (B) Sox2 expression. (C) Well-differentiated ACA with acinar
features and (D) absent Sox2 expression. (E) Poorly differentiated ACA with predominantly
solid pattern and (F) Sox2 expression. (G) Poorly differentiated ACA with predominantly
solid pattern and (H) absent Sox2 expression. Normal bronchial airways are present as
positive internal controls in panels D and H.
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Figure 2.
Time to progression in patients with lung adenocarcinoma based on Sox2 expression and
gender.
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Figure 3.
Overall survival in patients with lung adenocarcinoma based on Sox2 expression and
gender.
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Table 1
Clinicopathologic features of 104 patients with stage I lung adenocarcinoma.
Clinicopathologic
Parameter
n (%)
Total 104 (100)
Age
Median Age (Range) 68 (36–91)
Sex
 Male 38 (37)
 Female 66 (63)
Tobacco history*
 Smoker 85 (87)
 Never smoker 13 (13)
Surgical procedure
 Lobectomy 64 (62)
 Wedge resection 40 (38)
Stage†
 IA 52 (50)
 IB 51 (50)
Tumor grade
 Well 19 (18)
 Moderate 55 (53)
 Poor 30 (29)
Tumor heterogeneity
 Heterogeneous 85 (82)
 Homogeneous 19 (18)
Predominant histologic subtype
 Acinar 53 (51)
 Bronchioloalveolar 14 (13)
 Papillary 19 (18)
 Solid 18 (17)
Due to rounding, not all percentages total 100.
*
Smoking history was unavailable for 6 patients.
†
Distinction between stage IA and IB could not be made in one case.
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